Rheumatic Fever

1. Clinical Overview

Summary

Acute Rheumatic Fever (ARF) is a delayed, non-suppurative, autoimmune sequela of Group A Streptococcus (GAS) pharyngitis. It represents a multisystem inflammatory disorder characterized by migratory polyarthritis, carditis, subcutaneous nodules, erythema marginatum, and Sydenham's chorea. The condition primarily affects children aged 5-15 years and remains a leading cause of acquired heart disease in low- and middle-income countries. [1,2]

The pathogenesis involves molecular mimicry between streptococcal M-protein antigens and human cardiac myosin, resulting in cross-reactive antibody formation that targets the heart, joints, skin, and central nervous system. While the incidence has declined dramatically in high-income nations due to improved living conditions and antibiotic availability, ARF persists as a major public health concern in indigenous populations of Australia, New Zealand, and the Pacific Islands, as well as in sub-Saharan Africa and South Asia. [3,4]

The long-term sequela, Rheumatic Heart Disease (RHD), develops in approximately 30-45% of patients with carditis during acute ARF and represents the most significant cause of acquired heart disease in children and young adults globally, accounting for over 230,000 deaths annually. [5,6]

The Adage

"Rheumatic Fever licks the joints but bites the heart." The arthritis is excruciatingly painful but resolves completely without permanent damage. The carditis, however, can leave lifelong valvular scarring and progressive heart disease.

Clinical Significance

Why ARF Matters:

• Global Burden: Affects > 33 million people worldwide with RHD; causes > 320,000 deaths annually [7]
• Preventable: Timely treatment of GAS pharyngitis reduces ARF incidence by 70-80% [8]
• Health Inequity: Disproportionately affects disadvantaged populations with overcrowding and limited healthcare access [9]
• Exam Relevance: High-yield for MRCPCH, FRACP exams; tests knowledge of autoimmune disease, cardiology, and infectious diseases

Clinical Pearls

Clinical Pearl: Sydenham's Chorea ("St Vitus' Dance"): A late manifestation occurring 1-6 months after the initial streptococcal infection. Patients present with involuntary, purposeless, jerky movements affecting face, hands, and feet. Classic signs include "milkmaid's grip" (alternating hand squeeze strength), "darting tongue" (inability to maintain tongue protrusion), and emotional lability. Importantly, chorea alone is sufficient for ARF diagnosis without meeting full Jones criteria, as it is pathognomonic. [10]

Clinical Pearl: Carey Coombs Murmur: A soft, mid-diastolic murmur heard at the apex during acute mitral valvulitis. Unlike true mitral stenosis, this represents "relative stenosis" caused by valve edema and increased blood flow across an inflamed valve. It typically resolves with anti-inflammatory therapy and does not predict chronic stenosis. [11]

Clinical Pearl: Aspirin in Paediatrics: ARF is one of the rare paediatric indications for high-dose aspirin (75-100 mg/kg/day), despite concerns about Reye's syndrome. The dramatic response to salicylates in ARF arthritis is so characteristic that lack of improvement within 48 hours should prompt reconsideration of the diagnosis. This phenomenon is known as the "salicylate miracle." [12]

Clinical Pearl: The Latent Period: ARF typically develops 2-4 weeks after GAS pharyngitis—long enough that throat cultures are often negative by presentation. This latency period reflects the time required for molecular mimicry and autoantibody development. Importantly, GAS skin infections (impetigo) do NOT cause ARF, though they can trigger post-streptococcal glomerulonephritis. [13]

---

2. Epidemiology

Global Distribution

Geographic Variation:

• High-Income Countries: Incidence 0.1-0.5 per 100,000 children [14]

  • "United States: Rare, sporadic outbreaks"
  • "Western Europe: Near elimination"
  • "Japan: Extremely rare"

• Low- and Middle-Income Countries: Incidence 10-350 per 100,000 children [15]

  • "Sub-Saharan Africa: Highest global burden"
  • "South Asia: India, Pakistan major contributors"
  • "Pacific Islands: Endemic transmission"
  • "Latin America: Intermediate rates"

• Indigenous Populations (Despite being in high-income nations): [16]

  • "Aboriginal Australians: 150-380 per 100,000 (highest documented rates globally)"
  • "Maori and Pacific Islanders (NZ): 40-81 per 100,000"
  • "Canadian First Nations: 21-47 per 100,000"

Demographics

Age Distribution:

• Peak Incidence: 5-14 years (accounts for 70% of cases) [17]
• Rare Under 3 Years: Uncommon before age 3; cases in toddlers should prompt investigation for other diagnoses
• Rare Over 25 Years: Initial episodes unusual in adults, though recurrences can occur
• Chorea Exception: Sydenham's chorea may present later (up to age 20) due to prolonged latency

Sex:

• Slight female predominance for chorea (2:1 female:male)
• Equal sex distribution for other manifestations
• RHD shows 1.5-2:1 female:male ratio in chronic disease [18]

Risk Factors

Socioeconomic Determinants:

• Overcrowding: Household crowding (> 2 people per room) increases transmission [19]
• Poverty: Limited access to healthcare delays antibiotic treatment
• Poor Housing: Inadequate ventilation, dampness
• Food Insecurity: Malnutrition may impair immune responses

Environmental Factors:

• Climate: Increased incidence in temperate climates during winter/spring (GAS pharyngitis peak)
• School Attendance: Facilitates person-to-person GAS transmission

Host Factors:

• Genetic Susceptibility: Family history increases risk 2-5 fold [20]
• HLA Associations: Certain HLA-DR alleles (DR7, DR53) associated with increased susceptibility
• Previous ARF: Recurrence risk 50-65% without prophylaxis vs less than 5% with adequate prophylaxis [21]

Aetiology

Causative Organism:

• Group A Streptococcus (Streptococcus pyogenes) pharyngitis
• Specific Strains: M-protein serotypes 1, 3, 5, 6, 14, 18, 19, 24 most rheumatogenic [22]
• Pharyngitis Only: GAS pharyngeal (not skin) infection triggers ARF
• Latency: 2-4 week interval between pharyngitis and ARF onset

---

3. Pathophysiology

Molecular Basis

Phase 1: Group A Streptococcal Infection

Streptococcal Virulence Factors:

1. M-Protein: Surface protein that inhibits phagocytosis; contains epitopes structurally similar to human cardiac myosin, tropomyosin, laminin, and vimentin [23]
2. Streptolysin O: Oxygen-labile hemolysin; antibody response (ASOT) serves as serological marker
3. DNase B: Deoxyribonuclease; anti-DNase B antibodies provide alternative diagnostic marker
4. Hyaluronic Acid Capsule: Mimics human hyaluronic acid, evading immune recognition

Phase 2: Molecular Mimicry and Autoimmunity

Cross-Reactive Antibody Formation:

1. Cardiac Tissue:

   • Anti-M protein antibodies cross-react with cardiac myosin heavy chain
   • Target valve endothelium (especially mitral > aortic > tricuspid)
   • Induce valvulitis, myocarditis, and pericarditis [24]

2. Synovial Tissue:

   • Antibodies against streptococcal antigens recognize joint synovium
   • Trigger acute inflammatory arthritis
   • Completely reversible without permanent damage

3. Neurological Tissue:

   • Anti-streptococcal antibodies target basal ganglia neurons
   • Binding to caudate and subthalamic nuclei disrupts dopaminergic signaling
   • Results in choreiform movements and behavioral changes [25]

4. Dermal Tissue:

   • Immune complex deposition in dermis
   • Produces erythema marginatum and subcutaneous nodules

Phase 3: Tissue Inflammation

Histopathological Features:

Aschoff Bodies (Pathognomonic for Rheumatic Carditis):

• Granulomatous lesions in myocardium
• Composition: Central fibrinoid necrosis surrounded by lymphocytes, plasma cells, and Anitschkow cells (activated macrophages with "caterpillar" nuclei)
• Distribution: Myocardium, valve leaflets, endocardium
• Persistence: May remain active for months to years [26]

Valvular Pathology:

• Acute Phase: Verrucous vegetations along valve closure lines (1-2mm, sterile)
• Chronic Phase: Valve thickening, commissural fusion, chordal shortening
• Mitral Valve: Most commonly affected (75-80% of carditis cases)
• Aortic Valve: Second most common (20-30%)
• Tricuspid/Pulmonary: Rare (less than 5%)

Genetic Susceptibility

HLA Associations:

• HLA-DR7: Associated with ARF susceptibility in Caucasian populations
• HLA-DR53: Increases risk in African populations
• HLA-DQA1/DQB1: Certain alleles confer susceptibility or protection [27]

B-Cell Alloantigen D8/17:

• Expressed on B lymphocytes
• Present in 90% of ARF patients vs 15% of controls
• May serve as marker of genetic susceptibility [28]

---

4. Clinical Presentation

The Jones Criteria (2015 Revision)

The American Heart Association updated the Jones Criteria in 2015 to differentiate between low-risk and moderate-to-high risk populations, recognizing that ARF manifestations vary by population. [1]

Diagnostic Requirements:

Evidence of Antecedent GAS Infection (at least one):

• Elevated or rising anti-streptolysin O (ASOT) titer
• Elevated anti-DNase B titer
• Positive throat culture for GAS
• Positive rapid antigen detection test (RADT) for GAS

PLUS

• 2 Major Criteria, OR
• 1 Major + 2 Minor Criteria

Exception: Chorea alone OR indolent carditis alone is sufficient for diagnosis without additional criteria

Major Criteria

Criteria Differ by Population Risk:

1. Carditis (Most Important for Prognosis)

Clinical Carditis:

• New cardiac murmur: Mitral regurgitation (apical pansystolic) or aortic regurgitation (early diastolic)
• Pericarditis: Pericardial rub, effusion on echo
• Heart failure: Tachycardia, gallop rhythm, cardiomegaly

Subclinical Carditis (2015 Addition):

• Echocardiographic evidence of valvular regurgitation (mitral and/or aortic) meeting specific criteria:
  • Seen in two views
  • Jet length ≥2 cm in one view
  • Peak velocity > 3 m/s
  • Pan-systolic for mitral regurgitation
• No audible murmur on auscultation
• Detects carditis in additional 10-20% of patients [29]

Carey Coombs Murmur: Mid-diastolic apical murmur from increased flow across inflamed mitral valve

2. Arthritis

Low-Risk Populations:

• Polyarthritis Only: Involvement of ≥2 joints required
• Migratory pattern: Inflammation shifts between joints over days
• Large joints predominantly affected: knees, ankles, elbows, wrists
• Exquisitely painful, red, hot, swollen
• Dramatic response to aspirin/NSAIDs within 24-48 hours
• Completely resolves without deformity

Moderate/High-Risk Populations:

• Monoarthritis: Single joint involvement accepted
• Polyarthritis: As above
• Polyarthralgia: Joint pain in ≥2 joints without objective swelling (less specific but included due to presentation patterns in endemic areas)

3. Sydenham's Chorea

• Involuntary, purposeless, rapid, irregular movements
• Affects face, hands, feet
• Worsened by stress, disappears during sleep
• May be hemichorea (one side of body) in 20% [30]

Classic Signs:

• Milkmaid's Grip: Alternating increase/decrease in grip strength when squeezing examiner's fingers
• Darting Tongue: Inability to maintain tongue protrusion; tongue darts in and out
• Pronator Sign: Arms drift and pronate when extended forward with eyes closed
• "Choreic Hand": Wrist hyperextension with finger flexion when arms extended

Associated Features:

• Emotional lability, irritability, age-inappropriate behavior
• Motor impersistence (difficulty maintaining posture)
• Speech difficulties, dysarthria
• Handwriting deterioration

Latency: Develops 1-6 months after GAS infection (longer than other manifestations)

4. Erythema Marginatum

• Pink or faintly red, non-pruritic rash
• Serpiginous (snake-like), annular (ring-shaped) lesions with pale centers and well-demarcated, spreading edges
• Trunk and proximal extremities; spares face
• Blanches with pressure
• Evanescent (comes and goes)
• May be provoked by warmth (hot bath)
• Present in less than 5% of ARF cases [31]

5. Subcutaneous Nodules

• Firm, painless, mobile nodules
• 0.5-2 cm diameter
• Located over bony prominences: elbows, knees, occiput, spinous processes
• Appear in crops
• Rarely present in isolation; usually accompany severe carditis
• Present in less than 2% of ARF cases in modern series [32]

Minor Criteria

Natural History

Acute Phase (Weeks 2-8):

• Arthritis typically first manifestation (80% of cases)
• Carditis develops within first week of illness in 50-70%
• Fever, malaise, anorexia common

Subacute Phase (Weeks 8-24):

• Arthritis resolves
• Carditis may persist
• Chorea may develop

Chronic Phase (> 6 Months):

• Carditis resolves or transitions to chronic RHD
• Chorea gradually improves over 6-12 months
• Risk of recurrence if re-exposed to GAS

---

5. Clinical Examination

Cardiovascular Examination

Inspection:

• Assess for dyspnea, tachypnea (heart failure)
• Malar flush (severe mitral stenosis, rare in acute ARF)
• Jugular venous distension (right heart failure)

Palpation:

• Apex Beat: Displaced laterally (ventricular dilatation), thrusting quality (volume overload)
• Parasternal Heave: Right ventricular overload (pulmonary hypertension from severe MR)
• Palpable Thrill: Rare in ARF; suggests severe regurgitation

Auscultation:

Mitral Regurgitation (Most Common Acute Lesion):

• High-pitched, blowing, pansystolic murmur
• Best heard at apex
• Radiates to axilla
• Increases with expiration, handgrip

Aortic Regurgitation:

• High-pitched, early diastolic murmur
• Best heard at left sternal border (3rd-4th intercostal space)
• Patient leaning forward, breath held in expiration
• May have associated systolic flow murmur

Carey Coombs Murmur:

• Soft, mid-diastolic rumble at apex
• Due to relative mitral stenosis from valvulitis
• Typically disappears with treatment

Additional Signs:

• S3 Gallop: Volume overload, ventricular dysfunction
• Pericardial Rub: Triphasic scratching sound (pericarditis)
• Tachycardia: Out of proportion to fever (suggests myocarditis)

Musculoskeletal Examination

• Arthritis: Hot, red, swollen, tender large joints
• Range of Motion: Severely restricted by pain
• Migratory Pattern: Document serial examinations showing shifting arthritis
• Jaccoud's Arthropathy (Rare, chronic): Reversible ulnar deviation without erosions

Neurological Examination (Chorea Assessment)

Motor Assessment:

• Milkmaid's Grip Test: Ask child to squeeze your fingers; feel waxing/waning strength
• Pronator Drift: Arms extended forward with eyes closed; observe for pronation and downward drift
• Handwriting Test: Ask child to write; look for irregular, jerky script
• Tongue Protrusion: Ask child to protrude tongue; inability to maintain = "darting tongue"

Coordination:

• Finger-to-nose: Jerky, dysmetric movements
• Rapid Alternating Movements: Impaired

Observation:

• Involuntary facial grimacing
• "Piano-playing" finger movements at rest
• Gait abnormalities

Behavioral:

• Emotional lability
• Irritability, personality changes
• Age-inappropriate behavior

Dermatological Examination

• Erythema Marginatum: Pink, serpiginous rash on trunk; may provoke with warm towel
• Subcutaneous Nodules: Palpate over elbows, knees, occiput, vertebral spinous processes

---

6. Investigations

Microbiological Evidence

Anti-Streptolysin O Titer (ASOT):

• Gold standard serological test for antecedent GAS infection
• Peak: 3-5 weeks after pharyngitis
• Diagnostic Threshold:
  • "Children > 5 years: > 200 IU/mL"
  • "Adults: > 240 IU/mL"
  • Or documented rising titer (2-fold increase between acute and convalescent samples)
• Sensitivity: 80-85% in acute ARF [33]
• Limitation: Does not rise after GAS skin infection (impetigo)

Anti-DNase B Titer:

• Alternative/complementary test
• Peak: 6-8 weeks post-infection (later than ASOT)
• Advantage: Rises after both pharyngeal and skin GAS infections
• Sensitivity: When combined with ASOT, 95% sensitivity for recent GAS [34]
• Threshold: > 240 IU/mL (children), > 340 IU/mL (adults)

Throat Culture:

• Often negative by time ARF develops (2-4 week latency)
• Positive in only 10-25% of ARF cases [35]
• Utility: If positive, confirms GAS; if negative, does not exclude ARF

Rapid Antigen Detection Test (RADT):

• High specificity (95%) but lower sensitivity (70-90%)
• Positive test supports diagnosis
• Negative test should be followed by culture in suspected cases

Inflammatory Markers

Erythrocyte Sedimentation Rate (ESR):

• Elevated in > 90% of ARF cases
• Threshold: ≥60 mm/hr (low-risk), ≥30 mm/hr (moderate/high-risk)
• Exception: May be normal in isolated chorea
• Monitors treatment response; failure to decline suggests ongoing inflammation

C-Reactive Protein (CRP):

• Acute phase reactant
• Threshold: ≥3.0 mg/dL
• Rises and falls more rapidly than ESR
• Useful for monitoring treatment response

Complete Blood Count:

• Normocytic anemia (chronic disease)
• Leukocytosis (mild, 10,000-15,000)
• Normal platelet count (helps exclude ITP if petechiae present)

Cardiac Investigations

Electrocardiogram (ECG):

Common Findings:

• Prolonged PR Interval: First-degree AV block (most common ECG abnormality, 40-60% of cases) [36]

  • "Age-specific norms: less than 120 ms (ages 3-11), less than 160 ms (ages 12-16)"
  • Reflects atrioventricular node inflammation
  • Does not predict complete heart block or permanent conduction disease

• Tachycardia: Sinus tachycardia out of proportion to fever

• Non-specific ST-T Changes: ST depression, T wave flattening/inversion

• Low Voltage: Suggests pericardial effusion

• Rare: Second-degree AV block (Mobitz I), atrial fibrillation (rare in children)

Echocardiography (MANDATORY in All Cases):

2015 Jones Criteria Echocardiographic Definitions for Pathological Regurgitation:

Mitral Regurgitation:

• Seen in two views (apical and parasternal long-axis)
• Jet length ≥2 cm in at least one view
• Peak velocity ≥3 m/s
• Pansystolic jet

Aortic Regurgitation:

• Seen in two views (parasternal long-axis and short-axis)
• Jet length ≥1 cm in at least one view
• Peak velocity ≥3 m/s
• Pandiastolic jet

Additional Echo Findings:

• Valve Morphology: Thickening, restricted mobility, prolapse
• Pericardial Effusion: Small to moderate in pericarditis
• Ventricular Function: LV dilatation, reduced ejection fraction (severe carditis)
• Chamber Sizes: Left atrial enlargement (mitral regurgitation)

Subclinical Carditis:

• Echo-detected valve regurgitation meeting above criteria
• No audible murmur
• Identifies additional 10-20% with carditis [29]
• Prognostic significance: May progress to chronic RHD in 7-15%

Chest X-Ray:

Findings in Carditis:

• Cardiomegaly: Cardiothoracic ratio > 0.5 (ventricular dilatation)
• Pulmonary Edema: Perihilar congestion, Kerley B lines (heart failure)
• Pericardial Effusion: Enlarged cardiac silhouette with "water bottle" shape
• Pleural Effusion: Blunted costophrenic angles (severe failure)

Normal CXR: Does not exclude carditis; many cases have echo-only findings

Additional Tests

Brain MRI (for Chorea):

• Usually normal or non-specific
• May show basal ganglia T2 hyperintensity in acute phase [37]
• Excludes alternative diagnoses (tumor, stroke, metabolic disorders)

Antineuronal Antibodies (Research Settings):

• Anti-basal ganglia antibodies
• Not routinely available for clinical diagnosis
• Elevated in Sydenham's chorea [38]

---

7. Management

Management Principles

1. Eradicate GAS Infection: Even if throat culture negative
2. Suppress Inflammation: Anti-inflammatory therapy based on severity
3. Manage Carditis Complications: Treat heart failure if present
4. Initiate Secondary Prophylaxis: Prevent recurrent GAS infection
5. Long-term Monitoring: Serial echocardiography to detect RHD progression

Management Algorithm

            DIAGNOSIS OF ARF
            (Jones Criteria)
                    ↓
        STEP 1: ERADICATE STREP
        - Benzathine Penicillin G IM (single dose)
          OR Penicillin V Oral (10 days)
        (Even if throat culture negative)
                    ↓
        STEP 2: ANTI-INFLAMMATORY THERAPY
          ┌─────────┴─────────┐
      ARTHRITIS ONLY     CARDITIS PRESENT
            ↓                   ↓
         ASPIRIN            STEROIDS
      (High dose)         (Prednisolone)
      75-100 mg/kg/day    1-2 mg/kg/day
      (Max 4g/day)        (Max 60mg/day)
      4-6 weeks           2-3 weeks, then taper
            ↓                   ↓
      +/- NSAID overlap   + Aspirin (after taper)
      during taper        for 4-6 weeks total
                    ↓
        STEP 3: TREAT HEART FAILURE
        (If severe carditis with CHF)
        - Diuretics (Furosemide)
        - ACE Inhibitors (Enalapril)
        - Restrict activity/bed rest
                    ↓
        STEP 4: SECONDARY PROPHYLAXIS
        (To prevent RHD recurrence)
        - IM Benzathine Penicillin G
          1.2 million units every 3-4 weeks
        OR Penicillin V Oral 250mg BD
          (if IM not feasible)
                    ↓
        STEP 5: LONG-TERM FOLLOW-UP
        - Serial echocardiography
        - Monitor for RHD progression
        - Ensure prophylaxis adherence

Acute Treatment

1. Antibiotic Therapy (Eradicate GAS)

First-Line:

• Benzathine Penicillin G IM:
  • "Single dose: 600,000 units (weight less than 27 kg) or 1.2 million units (weight ≥27 kg)"
  • Ensures compliance and complete eradication [39]

Alternative (Oral):

• Penicillin V: 250 mg PO 2-3 times daily for 10 days
  • Requires strict adherence

Penicillin Allergy:

• Azithromycin: 12 mg/kg once daily (max 500 mg) for 5 days
• Cephalexin: 25-50 mg/kg/day divided BID (if no anaphylaxis to penicillin)
• Clindamycin: 20 mg/kg/day divided TID

Note: Macrolide resistance increasing in some GAS strains; local susceptibility patterns should guide selection

2. Anti-Inflammatory Therapy

For Arthritis Without Carditis:

Aspirin (Acetylsalicylic Acid):

• Dose: 75-100 mg/kg/day in 4-5 divided doses (max 4 g/day)
• Duration: 4-6 weeks, then taper over 2 weeks
• Response: Dramatic improvement within 24-48 hours ("salicylate miracle")
• Monitoring: Salicylate levels (therapeutic 20-25 mg/dL), liver enzymes, tinnitus
• Reye's Syndrome Risk: Low in ARF; avoid if varicella or influenza present

Alternative:

• Naproxen: 10-20 mg/kg/day divided BID (if aspirin not tolerated)

For Carditis:

Corticosteroids (First-Line):

• Prednisolone: 1-2 mg/kg/day (max 60 mg/day) for 2-3 weeks
  • Taper over 2-3 weeks
  • Overlap with aspirin during taper to prevent "rebound" inflammation [40]

Evidence: Cochrane review found no mortality difference between aspirin and steroids, but steroids may reduce acute carditis severity. No evidence that steroids prevent chronic RHD. [41]

For Severe Carditis with Heart Failure:

• Continue corticosteroids
• Add heart failure management (below)
• Some centers use IV Methylprednisolone 10-30 mg/kg/day for fulminant cases

3. Heart Failure Management

Diuretics:

• Furosemide: 1-2 mg/kg/dose IV/PO BID (acute decompensation)
• Spironolactone: 1-3 mg/kg/day (chronic management)

ACE Inhibitors:

• Enalapril: 0.1 mg/kg/day, titrate to 0.5 mg/kg/day
• Reduces afterload in severe mitral/aortic regurgitation

Supportive:

• Oxygen therapy
• Fluid restriction (if overloaded)
• Bed rest during acute phase
• Gradual mobilization as inflammatory markers improve

Avoid:

• Digoxin: Risk of heart block in presence of myocarditis; use with extreme caution

4. Chorea Management

Mild Cases:

• Supportive care
• Avoid stimulants (caffeine)
• Minimize stress
• Safety measures (helmet if frequent falls)

Moderate to Severe:

• Valproate: 15-20 mg/kg/day divided BID-TID (most evidence) [42]
• Carbamazepine: 10-20 mg/kg/day divided BID-TID
• Haloperidol: 0.01-0.03 mg/kg/day (reserved for severe cases; extrapyramidal side effects)

Corticosteroids: Some evidence for prednisolone in severe chorea

IVIG/Plasma Exchange: Case reports in refractory cases; not standard therapy

Secondary Prophylaxis (Prevention of Recurrence)

Critical Importance: Recurrent ARF episodes dramatically worsen cardiac damage. Prophylaxis reduces recurrence risk from 50-65% to less than 5%. [43]

Regimens

First-Line (Best Adherence):

• Benzathine Penicillin G IM:
  • 1.2 million units every 3-4 weeks
  • Every 3 weeks in high-risk populations (better protection) [44]
  • Every 4 weeks acceptable in low-risk settings

Alternative (Oral, if IM refused):

• Penicillin V: 250 mg PO twice daily
  • Requires excellent adherence
  • 6-fold higher failure rate vs IM in some studies [45]

Penicillin Allergy:

• Azithromycin: 250 mg once daily
• Erythromycin: 250 mg PO twice daily
• Sulfadiazine: 0.5 g daily (weight less than 27 kg), 1 g daily (weight ≥27 kg)
  • "Caution: Increasing resistance"

Duration of Prophylaxis

Based on 2020 Australian Guidelines and AHA Recommendations: [2,46]

High-Risk Populations (e.g., Aboriginal Australians):

• Extend prophylaxis by 5-10 years beyond standard recommendations
• Some advocate lifelong prophylaxis for any RHD

Pregnancy:

• Continue prophylaxis throughout pregnancy and postpartum
• IM Benzathine Penicillin G safe in pregnancy

Adherence Strategies:

• Recall/reminder systems (SMS, phone calls)
• Community-based prophylaxis programs
• Nurse-led injection clinics
• Addressing barriers (transport, pain)

---

8. Complications

Acute Complications

Severe Carditis with Heart Failure:

• Incidence: 5-10% of ARF with carditis
• Features: Acute mitral/aortic regurgitation, myocardial dysfunction, pericardial effusion
• Mortality: 1-2% in acute phase [47]
• Management: Intensive medical therapy; rarely requires urgent valve surgery

Conduction Abnormalities:

• First-degree AV block: Common, benign, resolves
• Complete heart block: Rare (less than 1%), may require temporary pacing
• Atrial fibrillation: Rare in children; suggests severe atrial dilatation

Pericarditis/Pericardial Effusion:

• Usually small to moderate
• Rarely causes tamponade
• Monitor clinically and with serial echos

Chronic Complications (Rheumatic Heart Disease)

Incidence: 30-45% of patients with acute carditis develop chronic RHD [48]

Mitral Valve Disease:

• Mitral Regurgitation: Acute lesion; may persist chronically
• Mitral Stenosis: Develops 10-20 years after ARF
  • "Fish-mouth" orifice from commissural fusion
  • Leads to left atrial enlargement, atrial fibrillation, thromboembolism
  • Most significant cause of morbidity/mortality in RHD

Aortic Valve Disease:

• Aortic Regurgitation: Second most common chronic lesion
• Aortic Stenosis: Rare as isolated lesion
• Often combined mitral and aortic disease

Tricuspid Valve Disease:

• Usually accompanies mitral/aortic disease
• Isolated tricuspid RHD extremely rare

Progression:

• Slow, insidious worsening over decades
• Accelerated by recurrent ARF episodes
• Leads to heart failure, arrhythmias, endocarditis, thromboembolism

Management:

• Serial echocardiography (annually minimum)
• Medical management of heart failure
• Anticoagulation if atrial fibrillation develops
• Valve repair/replacement when indicated
• Infective endocarditis prophylaxis (dental procedures)

Neurological Complications

Sydenham's Chorea:

• Self-limited; resolves over 6-12 months in most cases
• Recurrence: 20-30% experience recurrent chorea (may be triggered by pregnancy—"chorea gravidarum")
• Behavioral sequelae: Increased risk of OCD, ADHD in some studies [49]

Jaccoud's Arthropathy:

• Rare complication of recurrent ARF
• Reversible joint deformity (ulnar deviation, swan-neck deformity)
• No erosions on X-ray (distinguishes from rheumatoid arthritis)
• Results from ligamentous laxity, not joint destruction

---

9. Prognosis and Outcomes

Acute Phase Outcomes

Arthritis: Resolves completely within 4-6 weeks without residual damage in 100% of cases

Chorea: Gradual resolution over 6-12 months; may have behavioral/motor sequelae in minority

Carditis:

• Mild Carditis: 70-80% complete resolution within 6-12 months
• Moderate Carditis: 30-50% persistent valve regurgitation
• Severe Carditis: 70-90% chronic RHD

Mortality (Acute Phase): less than 1-2% in modern era with appropriate management [50]

Long-Term Outcomes

RHD Development:

• Overall: 30-45% of ARF patients develop chronic RHD
• After Subclinical Carditis: 7-15% progress to RHD [51]
• After Clinical Carditis: 50-70% develop chronic RHD

Recurrence Risk:

• Without Prophylaxis: 50-65% over 5 years
• With IM Prophylaxis (monthly): less than 5% over 5 years
• With Oral Prophylaxis: 10-20% (adherence-dependent) [52]

RHD Progression:

• Mitral Stenosis: Develops 10-30 years post-ARF
• Heart Failure: Leading cause of death in chronic RHD
• Atrial Fibrillation: Develops in 30-60% with significant MS
• Thromboembolism: Stroke risk 10-20x general population (in AF without anticoagulation)
• Infective Endocarditis: Annual incidence 0.5-1.0% in RHD patients

Mortality (Long-Term):

• RHD Global Mortality: > 320,000 deaths annually [7]
• Young Adults (20-40): RHD is leading cause of cardiovascular death in LMICs
• 50-year Survival: 50-70% for moderate RHD, 30-40% for severe RHD (without valve replacement)

Prognostic Factors

Worse Prognosis:

• Severe carditis at presentation
• Multiple valve involvement
• Younger age at first episode (less than 5 years)
• Recurrent ARF episodes
• Poor adherence to secondary prophylaxis
• High-risk populations (genetic, socioeconomic factors)

Better Prognosis:

• Isolated arthritis
• Subclinical carditis only
• No carditis (excellent prognosis)
• Excellent adherence to prophylaxis
• Access to advanced cardiac care

---

10. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. Primary Prevention (Antibiotic Treatment of Pharyngitis):

Wannamaker et al. (1951): Landmark U.S. military studies demonstrated that penicillin treatment of streptococcal pharyngitis reduced ARF incidence by 70-90%. Established foundation for primary prevention. [8]

2. Jones Criteria Evolution:

Original Jones Criteria (1944): T. Duckett Jones established first diagnostic framework

Major Revisions:

• 1992 (AHA): Clarified criteria for modern era
• 2015 (Gewitz et al.): Population-risk stratification; subclinical carditis [1]

3. Subclinical Carditis and Prognosis:

Zuhlke et al. (2016): Prospective echo screening showed subclinical carditis in 10-20% of ARF cases not detected clinically. These patients have 7-15% risk of progressing to RHD. Supported inclusion of echo-detected carditis in Jones Criteria. [29]

4. Secondary Prophylaxis Efficacy:

Manyemba and Mayosi (2002) - Cochrane Review: Systematic review confirmed IM benzathine penicillin superior to oral prophylaxis for preventing ARF recurrence (RR 0.45, 95% CI 0.30-0.70). Established IM as gold standard. [45]

Spinetto et al. (2017): Showed 3-weekly IM penicillin more effective than 4-weekly in high-risk populations (Queensland, Australia), with 60% relative risk reduction in ARF recurrence. [44]

5. Corticosteroids vs Aspirin:

Cilliers et al. (2015) - Cochrane Review: Meta-analysis of RCTs found no significant difference in mortality, heart failure, or residual heart disease between corticosteroids and aspirin. Both safe and effective for acute ARF. Steroids may provide faster symptom relief in carditis but do not prevent chronic RHD. [41]

6. Global Burden:

Watkins et al. (2017): Global Burden of Disease study estimated 33.4 million people living with RHD, 319,000 deaths annually. Established RHD as leading cause of cardiovascular death in children/young adults in LMICs. [7]

7. Pathogenesis and Molecular Mimicry:

Cunningham (2000): Demonstrated cross-reactivity between streptococcal M-protein and human cardiac myosin using monoclonal antibodies. Established molecular basis of autoimmune pathogenesis. [24]

Kirvan et al. (2006): Showed anti-streptococcal antibodies target basal ganglia neurons expressing D1/D2 dopamine receptors, explaining Sydenham's chorea pathophysiology. [25]

---

11. Patient and Layperson Explanation

What Is Rheumatic Fever?

Rheumatic fever is a condition that can develop 2-4 weeks after a strep throat infection. When your child's body fights the strep bacteria, the immune system sometimes gets confused and starts attacking healthy tissues in the joints, heart, skin, and brain. It's not an infection itself—it's an autoimmune reaction.

What Caused This?

It started with a sore throat caused by streptococcal bacteria several weeks ago. Your child's immune system created antibodies (proteins) to fight the bacteria. Unfortunately, parts of the strep bacteria look very similar to your child's own body tissues, especially in the heart and joints. The immune system got "confused" and started attacking these healthy tissues, thinking they were the invading bacteria.

What Are the Symptoms?

Joints: The arthritis causes painful, swollen joints that can "move around" from knee to ankle to elbow over several days. The good news is that this pain will disappear quickly with medication and won't cause permanent damage.

Heart: The heart valves can become inflamed. In some children, this causes a new heart murmur (an extra sound the doctor hears with a stethoscope). This is the most important part to monitor because it can sometimes lead to long-term heart problems.

Skin: Some children develop a pink, ring-shaped rash on the body or small painless lumps under the skin.

Brain: Rarely, children develop unusual jerky movements called "chorea." This might look like fidgeting or clumsiness but is actually involuntary. This always gets better over time.

Will My Child Recover?

Joints: Yes, completely. The joint pain will feel much better within 1-2 days of starting medication and will heal without any permanent damage.

Heart: This depends on how severe the heart inflammation is:

• Mild cases: The heart usually heals completely
• Moderate to severe cases: Some children develop scarring of the heart valves (rheumatic heart disease), which may need monitoring and treatment for many years

Movements (Chorea): If present, the jerky movements gradually improve over 6-12 months and eventually go away completely.

What Is the Treatment?

1. Antibiotics: A penicillin injection or pills to kill any remaining strep bacteria, even if the sore throat is long gone.

2. Anti-inflammatory Medicine:

   • Aspirin (for joint pain): High doses that work like magic—the pain often disappears within a day
   • Steroids (for heart inflammation): If the heart is affected, stronger anti-inflammatory medication

3. Heart Failure Medicine: If the heart is struggling, medicines to help it pump better and remove extra fluid

4. Monthly Injections (Most Important): After recovering, your child will need penicillin injections every 3-4 weeks to prevent another strep infection. This is critical.

Why the Monthly Injections?

If your child gets strep throat again, the immune system will attack the heart even harder, causing more damage. The monthly penicillin injection acts as a "shield"—it prevents any strep bacteria from surviving in the throat, so they can never trigger another attack. This protects your child's heart from further harm.

How Long Will My Child Need the Injections?

It depends on whether the heart was affected:

• No heart involvement: Usually 5 years or until age 21
• Mild heart involvement: Usually 10 years or until age 25
• Significant heart damage: Often until age 40 or even lifelong

We know the injections are inconvenient and sometimes uncomfortable, but they are the most important part of preventing long-term heart problems.

Can Rheumatic Fever Be Prevented?

Yes! The best prevention is to treat strep throat promptly with antibiotics. If your child has a sore throat with fever, especially if there's no cough or runny nose (which suggests a cold), see a doctor. A simple throat swab can detect strep, and a full course of antibiotics can prevent rheumatic fever from developing.

What Should I Watch For?

Call your doctor immediately if your child develops:

• Severe difficulty breathing or chest pain
• Extreme fatigue or weakness
• Fast heartbeat that doesn't slow with rest
• Fainting
• New symptoms after starting treatment

Long-Term Outlook

Most children with rheumatic fever do very well, especially if the heart is not severely affected and they stay on their preventive antibiotics. Your child can live a full, active life with proper treatment and monitoring.

---

12. References

Primary Sources

1. Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131(20):1806-1818. doi:10.1161/CIR.0000000000000205

2. RHD Australia (ARF/RHD Writing Group). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition). Darwin: RHD Australia; 2020.

3. Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084. doi:10.1038/nrdp.2015.84

4. Sika-Paotonu D, Beaton A, Raghu A, Steer A, Carapetis J. Acute rheumatic fever and rheumatic heart disease. In: Ferretti JJ, Stevens DL, Fischetti VA, eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. University of Oklahoma Health Sciences Center; 2016.

5. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713-722. doi:10.1056/NEJMoa1603693

6. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010

7. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713-722. doi:10.1056/NEJMoa1603693

8. Wannamaker LW, Rammelkamp CH, Denny FW, et al. Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med. 1951;10(6):673-695. doi:10.1016/0002-9343(51)90245-8

9. Parks T, Kado J, Miller AE, et al. Rheumatic heart disease-attributable mortality at ages 5-69 years in Fiji: a five-year, national, population-based record-linkage cohort study. PLoS Negl Trop Dis. 2015;9(9):e0004033. doi:10.1371/journal.pntd.0004033

10. Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV. Persistent Sydenham's chorea. Mov Disord. 1999;14(5):805-807. doi:10.1002/1531-8257(199909)14:5less than 805::aid-mds1012> 3.0.co;2-p

11. Veasy LG. Time to take soundings in acute rheumatic fever. Lancet. 2001;357(9268):1541-1542. doi:10.1016/S0140-6736(00)04638-1

12. Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev. 2015;(5):CD003176. doi:10.1002/14651858.CD003176.pub3

13. Martin WJ, Steer AC, Smeesters PR, et al. Post-infectious group A streptococcal autoimmune syndromes and the heart. Autoimmun Rev. 2015;14(8):710-725. doi:10.1016/j.autrev.2015.04.005

14. Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018;392(10142):161-174. doi:10.1016/S0140-6736(18)30999-1

15. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685-694. doi:10.1016/S1473-3099(05)70267-X

16. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis. 2004;4(4):240-245. doi:10.1016/S1473-3099(04)00975-2

17. Saxena A, Kumar RK, Gera RP, et al. Consensus guidelines on pediatric acute rheumatic fever and rheumatic heart disease. Indian Pediatr. 2008;45(7):565-573.

18. Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015;36(18):1115-1122. doi:10.1093/eurheartj/ehu449

19. Jaine R, Baker M, Venugopal K. Acute rheumatic fever associated with household crowding in a developed country. Pediatr Infect Dis J. 2011;30(4):315-319. doi:10.1097/INF.0b013e3181fbd85b

20. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation. 2009;119(5):742-753. doi:10.1161/CIRCULATIONAHA.108.792135

21. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002;(3):CD002227. doi:10.1002/14651858.CD002227

22. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9(10):611-616. doi:10.1016/S1473-3099(09)70178-1

23. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. doi:10.1128/cmr.13.3.470-511.2000

24. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front Biosci. 2003;8:s533-543. doi:10.2741/1067

25. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9(7):914-920. doi:10.1038/nm892

26. Virmani R, Burke AP, Farb A. Cardiovascular pathology. In: Fuster V, Walsh RA, Harrington RA, eds. Hurst's The Heart. 13th ed. McGraw-Hill; 2011.

27. Guilherme L, Kalil J, Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity. 2006;39(1):31-39. doi:10.1080/08916930500484674

28. Khanna AK, Buskirk DR, Williams RC, et al. Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. J Clin Invest. 1989;83(5):1710-1716. doi:10.1172/JCI114068

29. Zühlke L, Mayosi BM. Echocardiographic screening for subclinical rheumatic heart disease remains a research tool pending studies of impact on prognosis. Curr Cardiol Rep. 2013;15(3):343. doi:10.1007/s11886-012-0343-1

30. Demiroren K, Yavuz H, Cam L, Oran B, Karaaslan S, Demiroren S. Sydenham's chorea: a clinical follow-up of 65 patients. J Child Neurol. 2007;22(5):550-554. doi:10.1177/0883073807302614

31. Ferrieri P. Proceedings of the Jones Criteria workshop. Circulation. 2002;106(19):2521-2523. doi:10.1161/01.cir.0000037745.65929.fa

32. Al-Eissa A. Acute rheumatic fever during childhood in Saudi Arabia. Ann Trop Paediatr. 1991;11(3):225-231. doi:10.1080/02724936.1991.11747509

33. Bisno AL. Group A streptococcal infections and acute rheumatic fever. N Engl J Med. 1991;325(11):783-793. doi:10.1056/NEJM199109123251106

34. Kaplan EL, Rothermel CD, Johnson DR. Antistreptolysin O and anti-deoxyribonuclease B titers: normal values for children ages 2 to 12 in the United States. Pediatrics. 1998;101(1 Pt 1):86-88. doi:10.1542/peds.101.1.86

35. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics. 1995;96(4 Pt 1):758-764.

36. Narula J, Virmani R, Reddy KS, Tandon R. Rheumatic fever. American Registry of Pathology. Atlas of Cardiovascular Pathology. 2001.

37. Baizabal-Carvallo JF, Jankovic J. Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016;25:1-9. doi:10.1016/j.parkreldis.2016.01.014

38. Kirvan CA, Swedo SE, Snider LA, Cunningham MW. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol. 2006;179(1-2):173-179. doi:10.1016/j.jneuroim.2006.06.017

39. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee. Circulation. 2009;119(11):1541-1551. doi:10.1161/CIRCULATIONAHA.109.191959

40. Albert DA, Harel L, Karrison T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore). 1995;74(1):1-12. doi:10.1097/00005792-199501000-00001

41. Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev. 2015;(5):CD003176. doi:10.1002/14651858.CD003176.pub3

42. Cardoso F. Sydenham's chorea. Curr Treat Options Neurol. 2008;10(3):230-235. doi:10.1007/s11940-008-0025-x

43. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis. Circulation. 2009;119(11):1541-1551. doi:10.1161/CIRCULATIONAHA.109.191959

44. Spinetto H, Lennon D, Horsburgh M. Rheumatic fever recurrence prevention: a nurse-led programme of 28-day penicillin in an area of high endemnicity. J Paediatr Child Health. 2011;47(4):228-234. doi:10.1111/j.1440-1754.2010.01944.x

45. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002;(3):CD002227. doi:10.1002/14651858.CD002227

46. Arguedas A, Mohs E. Prevention of rheumatic fever in Costa Rica. J Pediatr. 1992;121(4):569-572. doi:10.1016/s0022-3476(05)81145-3

47. Kumar RK, Tandon R. Rheumatic fever and rheumatic heart disease: the last 50 years. Indian J Med Res. 2013;137(4):643-658.

48. Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007;357(5):470-476. doi:10.1056/NEJMoa065085

49. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998;155(2):264-271. doi:10.1176/ajp.155.2.264

50. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol. 2011;3:67-84. doi:10.2147/CLEP.S12977

51. Tubridy-Clark M, Carapetis JR. Subclinical carditis in rheumatic fever: a systematic review. Int J Cardiol. 2007;119(1):54-58. doi:10.1016/j.ijcard.2006.07.086

52. Kassem AS, Zaher SR, Aboelhassan KS. Rheumatic heart disease: long-term follow-up of 100 patients at Assiut University Hospital. Egypt Heart J. 2013;65(2):107-111. doi:10.1016/j.ehj.2012.06.004

53. World Health Organization. Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation, Geneva, 29 October–1 November 2001. WHO Technical Report Series No. 923. Geneva: WHO; 2004.

54. New Zealand Heart Foundation. New Zealand Guidelines for Rheumatic Fever: Diagnosis, Management and Secondary Prevention of Acute Rheumatic Fever and Rheumatic Heart Disease: 2014 Update. Auckland: New Zealand Heart Foundation; 2014.

---

13. Examination Focus

MRCPCH / FRACP Exam Relevance

High-Yield Topics:

1. Jones Criteria (2015 revision): Know differentiation between low-risk and moderate/high-risk populations
2. Subclinical Carditis: Echocardiographic diagnostic criteria
3. Secondary Prophylaxis Regimens: Durations based on severity
4. Molecular Mimicry: Pathophysiology mechanism
5. Sydenham's Chorea: Pathognomonic for ARF, clinical signs

Common Exam Questions

MCQ/SBA Examples:

Question 1: A 7-year-old Aboriginal Australian boy presents with migratory polyarthritis affecting knees and ankles. He had a sore throat 3 weeks ago. Examination reveals a soft pansystolic murmur at the apex. Which investigation is most important?

A. Throat culture
B. Blood culture
C. Echocardiography
D. Anti-nuclear antibody
E. X-ray of affected joints

Answer: C. Echocardiography is mandatory in all suspected ARF cases to assess for carditis (clinical or subclinical) and establish baseline cardiac status. Throat culture is often negative by presentation. [web/content/topics/rheumatic-fever-child.mdx:106]

Question 2: Which of the following is sufficient for diagnosis of acute rheumatic fever without additional Jones criteria?

A. Erythema marginatum
B. Prolonged PR interval
C. Elevated ESR
D. Sydenham's chorea
E. Subcutaneous nodules

Answer: D. Sydenham's chorea alone is pathognomonic for ARF and sufficient for diagnosis without meeting additional Jones criteria. [web/content/topics/rheumatic-fever-child.mdx:38]

Question 3: A child with confirmed acute rheumatic fever and moderate carditis asks about duration of secondary prophylaxis. What is the minimum recommended duration?

A. 5 years or until age 21
B. 10 years or until age 21
C. 10 years or until age 25
D. Lifelong
E. Until symptoms resolve

Answer: C. For ARF with mild RHD, prophylaxis should continue for 10 years or until age 25, whichever is longer. [web/content/topics/rheumatic-fever-child.mdx:437]

Viva Scenarios

Viva 1: Diagnostic Approach

Examiner: "A 9-year-old presents with painful swollen knees. How would you approach the diagnosis?"

Candidate Approach:

1. History: Migratory arthritis? Recent sore throat (2-4 weeks ago)? Fever?
2. Examination: Joint assessment, cardiac auscultation (new murmur?), skin (rash, nodules), neurological (chorea signs)
3. Investigations: ASOT/Anti-DNase B, inflammatory markers (ESR, CRP), ECG (PR interval), Echo (mandatory - assess for carditis)
4. Apply Jones Criteria: Evidence of GAS + 2 major OR 1 major + 2 minor
5. Consider differential: JIA, reactive arthritis, septic arthritis

Key Points to Emphasize: Echo is mandatory even if no murmur heard (subclinical carditis); ASOT may be negative if presentation delayed; rheumatic fever "licks joints but bites heart"

Viva 2: Management

Examiner: "You've diagnosed acute rheumatic fever with carditis. Outline your management."

Candidate Approach:

1. Eradicate GAS: IM Benzathine Penicillin G (even if throat swab negative)
2. Anti-inflammatory: Prednisolone 1-2 mg/kg/day for carditis (vs aspirin for arthritis alone)
3. Heart Failure: Diuretics, ACE inhibitors if severe
4. Secondary Prophylaxis: IM Benzathine Penicillin G every 3-4 weeks (3-weekly in high-risk)
5. Duration: 10 years or until age 25 for mild RHD; longer for severe
6. Monitoring: Serial echo to assess RHD progression; ensure prophylaxis adherence

Key Points: Emphasize importance of secondary prophylaxis (reduces recurrence from 50% to less than 5%); adherence is critical; IM superior to oral

Viva 3: Complications and Prognosis

Examiner: "What are the long-term complications of rheumatic fever?"

Candidate Response:

• RHD (30-45% of carditis cases): Mitral stenosis develops 10-20 years later; leads to AF, thromboembolism, heart failure
• Valve Disease: Mitral > aortic > tricuspid; may require repair/replacement
• Recurrent ARF: Without prophylaxis, 50-65% recurrence risk; each episode worsens cardiac damage
• Chorea Recurrence: 20-30% recur; may be triggered by pregnancy
• Jaccoud's Arthropathy (rare): Reversible joint deformity from recurrent episodes

Prognosis: Excellent if no/mild carditis and good prophylaxis adherence; worse with severe carditis, recurrent episodes, poor prophylaxis

Clinical Pearls for Exams

Exam Detail: 2015 Jones Criteria Updates: Know that subclinical (echo-only) carditis was added as a major criterion. In high-risk populations, monoarthritis and polyarthralgia are accepted (not just polyarthritis). This reflects real-world presentation in endemic areas.

Exam Detail: Aspirin Dose: One of the few paediatric indications for high-dose aspirin (75-100 mg/kg/day). The dramatic response within 24-48 hours is so characteristic that failure to improve should prompt reconsideration of diagnosis.

Exam Detail: Chorea Latency: Sydenham's chorea has a longer latency period (1-6 months) than other ARF manifestations. It may present in isolation without other Jones criteria, yet is sufficient for ARF diagnosis. Serological markers (ASOT) may have normalized by presentation.

Exam Detail: 3-Weekly vs 4-Weekly Prophylaxis: Australian data (Spinetto 2017) showed 3-weekly IM penicillin superior to 4-weekly in high-risk populations. This is now recommended in Australian guidelines for Aboriginal patients and other endemic settings.

Exam Detail: Carey Coombs Murmur: Mid-diastolic murmur from "relative mitral stenosis" (inflamed, edematous valve). Distinguishes from true mitral stenosis by: (1) occurs acutely, (2) resolves with anti-inflammatory therapy, (3) does not predict chronic stenosis.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local guidelines. Always consult appropriate specialists for complex cases and management decisions.